Literature DB >> 17625570

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Manabu Soda1, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Masashi Bando, Shoji Ohno, Yuichi Ishikawa, Hiroyuki Aburatani, Toshiro Niki, Yasunori Sohara, Yukihiko Sugiyama, Hiroyuki Mano.   

Abstract

Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells. Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumours in nude mice. The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examined; these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic molecular marker in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17625570     DOI: 10.1038/nature05945

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1865 in total

1.  Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Authors:  Hong Lou; Hongchuan Li; Meredith Yeager; Kate Im; Bert Gold; Thomas D Schneider; Joseph F Fraumeni; Stephen J Chanock; Stephen K Anderson; Michael Dean
Journal:  Hum Genet       Date:  2012-06-04       Impact factor: 4.132

2.  Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2.

Authors:  Seizo Koshiba; Hua Li; Yoko Motoda; Tadashi Tomizawa; Takuma Kasai; Naoya Tochio; Takashi Yabuki; Takushi Harada; Satoru Watanabe; Akiko Tanaka; Mikako Shirouzu; Takanori Kigawa; Tadashi Yamamoto; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2010-05-08

Review 3.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

4.  Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.

Authors:  Ting Ye; Yunjian Pan; Rui Wang; Haichuan Hu; Yang Zhang; Hang Li; Lei Wang; Yihua Sun; Haiquan Chen
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

5.  Contrast agents for quantitative microCT of lung tumors in mice.

Authors:  Kush Lalwani; Anand Giddabasappa; Danan Li; Peter Olson; Brett Simmons; Farbod Shojaei; Todd Van Arsdale; James Christensen; Amy Jackson-Fisher; Anthony Wong; Patrick B Lappin; Jeetendra Eswaraka
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

6.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

Authors:  Martin L Sos; Felix Dietlein; Martin Peifer; Jakob Schöttle; Hyatt Balke-Want; Christian Müller; Mirjam Koker; André Richters; Stefanie Heynck; Florian Malchers; Johannes M Heuckmann; Danila Seidel; Patrick A Eyers; Roland T Ullrich; Andrey P Antonchick; Viktor V Vintonyak; Peter M Schneider; Takashi Ninomiya; Herbert Waldmann; Reinhard Büttner; Daniel Rauh; Lukas C Heukamp; Roman K Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

7.  Transforming mutations of RAC guanosine triphosphatases in human cancers.

Authors:  Masahito Kawazu; Toshihide Ueno; Kenji Kontani; Yoshitaka Ogita; Mizuo Ando; Kazutaka Fukumura; Azusa Yamato; Manabu Soda; Kengo Takeuchi; Yoshio Miki; Hiroyuki Yamaguchi; Takahiko Yasuda; Tomoki Naoe; Yoshihiro Yamashita; Toshiaki Katada; Young Lim Choi; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

8.  Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

Authors:  Eiji Iwama; Yasushi Goto; Haruyasu Murakami; Shinsuke Tsumura; Hiroyuki Sakashita; Yoshiaki Mori; Noriaki Nakagaki; Yuka Fujita; Masahiro Seike; Akihiro Bessho; Manabu Ono; Masaru Nishitsuji; Hiroaki Akamatsu; Ryotaro Morinaga; Takanori Akagi; Takayuki Shimose; Shoji Tokunaga; Nobuyuki Yamamoto; Yoichi Nakanishi; Kenji Sugio; Isamu Okamoto
Journal:  Oncologist       Date:  2019-10-30

9.  Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.

Authors:  Yuan-Yuan Lei; Jin-Ji Yang; Wen-Zhao Zhong; Hua-Jun Chen; Hong-Hong Yan; Jie-Fei Han; Lu-Lu Yang; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 10.  Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Cancer J       Date:  2015 Sep-Oct       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.